A recent Food and Drug Administration regulation has resulted in the availability of 3 new standardized pancreatic enzyme products with proven short-term efficacy and safety (Creon®, Pancreaze®, and Zenpep®). They comply with modern chemistry, manufacturing, and control criteria, including predictable amounts of enzyme content. However, they differ in available strengths, are not designated by Food and Drug Administration as therapeutically equivalent, and are not interchangeable by pharmacists without previous approval of the prescriber.
HendelesL, HochhausG, KazerounianS. Generic and alternative brand-name pharmaceutical equivalents: select with caution. Am J Hosp Pharm, 1993; 50:323–329.
6.
GrahamDY. An enteric-coated pancreatic enzyme preparation that works. Dig Dis Sci, 1979; 24:906–909.
7.
MischlerEH, ParrellS, FarrellPM, OdellGB. Comparison of effectiveness of pancreatic enzyme preparations in cystic fibrosis. Am J Dis Child, 1982; 136:1060–1063.
8.
LittlewoodJM, KelleherJ, WaltersMP, JohnsonAW. In vivo and in vitro studies of microsphere pancreatic supplements. J Pediatr Gastroenterol Nutr, 1988; 7,Suppl 1:S22–S29.
9.
KraisingerM, HochhausG, StecenkoA, BowserE, HendelesL. Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations. J Clin Pharmacol, 1994; 34:158–166.
10.
HendelesL, DorfA, StecenkoA, WeinbergerM. Treatment failure after substitution of generic pancrelipase capsules. Correlation with in vitro lipase activity. JAMA, 1990; 263:2459–2461.
11.
FDA. Discussion of appropriate testing procedures for exocrine pancreatic insufficiency drug products; workshop and reopening of the administrative record. Fed Regist, 1992; 57:8586–8588.
12.
SmythRL, van VelzenD, SmythAR, LloydDA, HeafDP. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet, 1994; 343:85–86.
13.
OadesPJ, BushA, OngPS, BreretonRJ. High-strength pancreatic enzyme supplements and large-bowel stricture in cystic fibrosis (letter)Lancet, 1994; 343:109.
14.
CampbellCA, ForrestJ, MusgroveC. High-strength pancreatic enzyme supplements and large-bowel stricture in cystic fibrosis (letter)Lancet, 1994; 343:109–110.
15.
BorowitzDS, GrandRJ, DuriePR. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. J Pediatr, 1995; 127:681–684.
16.
PrescottP, BakowskiMT. Pathogenesis of fibrosing colonopathy: the role of methacrylic acid copolymer. Pharmacoepidemiol Drug Saf, 1999; 8:377–384.
17.
FitzSimmonsSC, BurkhartGA, BorowitzD, GrandRJ, HammerstromT, DuriePRet al.High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med, 1997; 336:1283–1289.
18.
FDA. Exocrine pancreatic insufficiency drug products for over-the-counter human use; proposed rulemaking. Fed Regist, 1991; 56:32282–32290.
19.
FDA. Exocrine pancreatic insufficiency drug products for over-the-counter human use; final rule. Fed Regist, 1995; 60:20162–20165.
20.
FDA. Exocrine pancreatic insufficiency drug products. Fed Regist, 2004; 69:23410–23414.
21.
CaseCL, HennigesF, BarkinJS. Enzyme content and acid stability of enteric-coated pancreatic enzyme products in vitro. Pancreas, 2005; 30:180–183.
22.
KuhnRJ, EytingS, HennigesF, PotthoffA. In vitro comparison of physical parameters, enzyme activity, acid resistance, and pH dissolution characteristics of enteric-coated pancreatic enzyme preparations: implications for clinical variability and pharmacy substitution. J Pediatr Pharmacol Ther, 2007; 12:115–128.
ForestiR, PelosoL, AnelliM. Overfilling in pancreatic enzyme preparations: still an unresolved issue. J Cyst Fibros, 2007; 6,Suppl 1:S60.
25.
BorowitzD, KonstanMW, O'RourkeA, CohenM, HendelesL, MurrayFT. Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis. J Pediatr Pharmacol Ther, 2007; 12:47–52.
26.
BakerSS, BorowitzD, DuffyL, FitzpatrickL, GyamfiJ, BakerRD. Pancreatic enzyme therapy and clinical outcomes in patients with cystic fibrosis. J Pediatr, 2005; 146:189–193.
27.
TrapnellBC, MaguinessK, GraffGR, BoydD, BeckmannK, CarasS. Efficacy and safety of Creon® 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros, 2009; 8:370–377.
28.
WooldridgeJL, HeubiJE, Amaro-GalvezR, BoasSR, BlakeKV, NasrSZet al.EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. J Cyst Fibros, 2009; 8:405–417.
